Anderson I M, Clark L, Elliott R, Kulkarni B, Williams S R, Deakin J F (2002) 5-HT (2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI . NeuroReport13: 1547–1551
2.
European Agency for the Evaluation of Medicinal Products (2002) Notes for guidance on good clinical practice (CPMP/ICH/139/95). http://www.emea.eu.int/pdfs/human/ich/013595en.pdf (accessed 8 March 03)
3.
Gijsman H J, Cohen A F, van Gerven J M A (2004) The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system . J Psychopharmacol18: 5–10
4.
Medicines Control Agency (2003) Consultation on the UK’s proposed implementing Regulations for the Clinical Trials Directive (2000/20/EC). http://www.doh.gov.uk/clinicaltrialsconsult/ (accessed 8 March 03)
5.
Seibyl J P, Krystal J H, Price L H, Woods S W, D’Amico C, Heninger G R, Charney D S (1991) Effects of ritanserin on the behavioral, neuroendocrine and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects . Psychiatry Res38: 227–236
6.
Silverstone P H, Rue J E, Franklin M, Hallis K, Camplin G, Laver D, Cowen P J (1994) The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers . Int Clin Psychopharmacol9: 173–178
